Psoriasis Comorbidities and Their Treatment Impact.

Psoriasis, a systemic inflammatory disease classically presenting with cutaneous lesions, has significant involvement in other organ systems. This article explores the prevalence, clinical manifestations, screening mechanisms, and laboratory testing by which to evaluate these comorbidities. Treatment approach for these comorbidities must combine patient preference with established treatment algorithms while recognizing innovative therapeutics currently under development.

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure M. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, United States, Amgen, United States, Arcutis, Avotres, Boehringer Ingelheim, United States, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, United States, Inozyme, Janssen Research & Development, United States, LLC, Ortho Dermatologics, United States, Pfizer, United States, Sanofi-Regeneron, and UCB, Belgium, and is a consultant for Almirall, AltruBio Inc, AnaptysBio, Apogee, Arcutis, Inc, AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc, Facilitation of International Dermatology Education, Forte biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. M. Taliercio is an employee of Mount Sinai.